MAPT and Alzheimer disease: Interestingly, in a preclinical model of AD, withaferin A reduced tau protein aggregation and amyloid oligomer formation properties by engaging chaperone proteins, such as Heat shock protein 70 and 90 (Hsp70/Hsp90, respectively) [33].